Incretins

Subscribe to Selected New Research on Incretins

173 relevant articles (10 outcomes, 12 trials/studies) found for this Bio-Agent

Description: Peptides which stimulate INSULIN release from the PANCREATIC BETA CELLS following oral nutrient ingestion, or postprandially.

Also Known As:

Incretin; Glucose Dependent Insulin Releasing Hormone; Hormone, Glucose-Dependent Insulin-Releasing; Insulin-Releasing Hormone, Glucose-Dependent; Glucose-Dependent Insulin-Releasing Hormone

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses

Pharmacologic Actions: 50

Physiological Effects of Drugs: 1

Hormones, Hormone Substitutes, and Hormone Antagonists

Hormones: 44075

Incretins: 173

Experts

1.	Holst, J J: 6 articles (04/2007 - 09/2001)
2.	Vilsbøll, Tina: 4 articles (07/2008 - 11/2004)
3.	Holst, Jens J: 4 articles (07/2008 - 03/2002)
4.	Vilsbøll, T: 3 articles (04/2007 - 06/2003)
5.	Perusicová, J: 2 articles (10/2007 - 09/2007)
6.	Krarup, T: 2 articles (04/2007 - 06/2003)
7.	Madsbad, S: 2 articles (04/2007 - 06/2003)
8.	Gallwitz, B: 2 articles (06/2006 - 09/2005)
9.	Astrup, A: 2 articles (01/2003 - 08/2001)
10.	Chia, Chee W: 1 article (10/2008)

Related Diseases

1.	Weight Loss (Weight Reduction) 04/01/2008 - "Only incretin-mimetics have a lowering HbA1c action, due to the improvement in beta-cell function, which is coupled to significant weight loss" 02/01/2006 - "The incretin mimetics, administered by sc injection, have demonstrated lasting improvement in HbA(1)c in patients insufficiently treated with conventional oral therapy, and their use has been associated with steady weight loss for up to 2 years" 07/01/2008 - "OBJECTIVE: Our objective was to determine whether the magnitude of the change of the incretin levels and effect is greater after GBP compared with a low caloric diet, after equivalent weight loss" 07/01/2008 - "Diet-induced weight loss also improves T2DM and may increase incretin levels" 02/01/2008 - "Also, new antihyperglycemic agents, such as incretin-related therapies, have the potential to address the unmet needs associated with conventional antihyperglycemic agents, including the improvement of glycemic control with either weight maintenance or weight loss and the modification of CMR factors" Get all the results and reference details, order at left...
2.	Insulin Resistance 10/01/2008 - "The insulin resistance reversion is only partially explained by the incretin level changes after BPD" 02/01/2007 - "Though abnormal gastric motility is related to HOMA-R, the findings herein suggest that incretin, showing insulin resistance, or an adipocyokine might be related to the differences in EGG in both groups" 09/01/2001 - "Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men." 05/01/2005 - "We have previously proposed that the rapid improvement in insulin resistance observed following bariatric surgery is mediated by changes in incretin levels of the entero-insular axis and that long-term improvement is modulated by fat mass loss and changes in adipocytokine levels of the adipoinsular axis" 09/01/2001 - "Multiple linear regression analysis showed that insulin resistance, but not obesity, was an independent predictor of these decreased incretin responses" Get all the results and reference details, order at left...
3.	Type 2 Diabetes Mellitus (MODY) 10/01/2008 - "Incretin-based therapies in type 2 diabetes mellitus." 07/01/2008 - "Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility." 06/01/2008 - "Incretin based therapies for type 2 diabetes mellitus." 04/12/2008 - "In type 2 diabetes mellitus, the incretin response is decreased" 04/01/2008 - "One should first of all mention the DPP4-inhibitors and the incretin mimetics, which have the potential of restoring the incretin effect in patients with type 2 diabetes mellitus" Get all the results and reference details, order at left...
4.	Hyperglycemia 11/01/2008 - "Inhibition of this enzyme results in an increase in the half-life and the sustained physiologic action of incretins, leading to an improvement in hyperglycemia" 06/01/2008 - "The actions of incretin-based drugs predominantly target postprandial hyperglycemia" 10/01/2006 - "Physiology, pathophysiology and therapeutic implications of incretins in diabetes, neurodegenerative disorders and stress-induced hyperglycemia are concerned." 12/01/2007 - "The incretin-based therapies can favorably impact some underlying elements in T2DM pathophysiology, including glucagon hypersecretion, rapid gastric emptying, postprandial hyperglycemia, and, possibly, chronic -cell dysfunction" 11/01/2004 - "These effects may be of considerable importance in the treatment of postprandial hyperglycemia although they are not, strictly speaking, the result of a direct incretin effect on glucose metabolism." Get all the results and reference details, order at left...
5.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 06/15/2005 - "Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans." 04/01/2006 - "Recent studies in adult patients with type 1 diabetes mellitus (T1DM) and T2DM have examined the potential utility, benefits, and side effects of agents that augment insulin secretion after oral ingestion of nutrients in comparison with intravenous nutrient delivery, the so-called incretins" 06/15/2005 - "The remission phase of Type 1 diabetes mellitus is associated with substantial recovery of beta-cell function and with marked improvement of endogenous insulin responses to meals in the early months after diagnosis, accompanied by little or no improvement in the insulin response to parenteral glucose, suggesting that the incretin function may be important in glycaemic regulation in this phase of diabetes" Get all the results and reference details, order at left...
39 Diseases and 173 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Glucose (Dextrose)
2.	Insulin (Novolin)
3.	Hormones
4.	Metformin (Glucophage)
5.	exenatide (Byetta)
6.	Glucagon-Like Peptide 1 (GLP 1)
7.	Thiazolidinediones
8.	vildagliptin
9.	Glucagon (Glukagon)
10.	glucagon-like peptide receptor (receptor, glucagon-like peptide)
63 Drugs and Important Bio-Agents and 133 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Bariatric Surgery
2.	Transplantation (Transplant Recipients)
3.	Gastric Bypass (Roux-en-Y Gastric Bypass)
4.	Biliopancreatic Diversion
5.	Parenteral Nutrition
7 Therapies and Procedures and 8 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>